Accessibility Menu
CelLBxHealth Plc logo

CelLBxHealth Plc(LSE) AGL

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-99%
5 Year-99%
1 Year-79%
1 Month-17%
N/A
CelLBxHealth Plc last closing stock price
MetricPriceDate
Last closeGBX 1.272026-07-30
CelLBxHealth Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%GBX 1.272026-07-23
1 month-16.99%GBX 1.532026-06-30
3 month+41.11%GBX 0.902026-05-01
Year to date+15.45%GBX 1.102025-12-31
1 year-78.83%GBX 6.002025-07-30
3 year-91.24%GBX 14.502023-07-31
5 year-98.84%GBX 109.252021-07-30
Since inception-99.15%GBX 1.492004-03-17

CelLBxHealth Plc Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£2.27M

Net Income (TTM)

-£22.77M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Apr 23, 2026

AGL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CelLBxHealth Plc

CelLBxHealth plc is a healthcare company focused on cancer diagnostics and fetal health. The company specializes in innovative technologies, particularly the Parsortix cell separation system, which captures rare cells from blood samples.

Products and Services
  • Parsortix cell separation system for cancer diagnostics
  • Innovative solutions for fetal health monitoring
  • Research and development in medical technologies
Growth Outlook
  • Recent quarterly revenue increased to £555,000, showing potential for growth
  • Cash and cash equivalents rose to £7.35 million, enhancing liquidity
  • Focus on expanding product offerings in cancer diagnostics and fetal health
Financial Highlights
  • Trailing twelve months revenue of £1.85 million indicates market interest
  • Net income for Q4 2025 was -£10.24 million, reflecting ongoing investment
  • Operating cash flow improved, signaling better operational efficiency
CelLBxHealth plc operates in a vital sector, addressing significant healthcare challenges through its advanced diagnostic technologies. The Parsortix system is particularly noteworthy for its ability to isolate rare cells, which can be crucial for early cancer detection. The company's recent financial performance, while showing losses, indicates a commitment to growth and innovation, as evidenced by the increase in revenue and cash reserves. The focus on expanding product offerings positions CelLBxHealth as a potential leader in the medical distribution industry, particularly in cancer diagnostics and fetal health. Investors may find the company's trajectory and innovative solutions appealing as it navigates the complexities of the healthcare market.
AI Generated • Jul 7, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

119

CEO

Peter Collins

Website

www.angleplc.com

Headquarters

Guildford, RG1 8LS, GB

AGL Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

-224.18%

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-£3.36M

Operating Income

-£28.44M

EBITDA

-£18.17M

Operating Cash Flow

-£12.56M

Capital Expenditure

-£357.00K

Free Cash Flow

-£12.92M

Cash & ST Invst.

£7.35M

Total Debt

£1.82M

CelLBxHealth Plc Performance Analysis

CelLBxHealth Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 1,041,0002.8%
20232023-12-31GBP 2,186,000110.0%
20242024-12-31GBP 2,862,00030.9%
20252025-12-31GBP 1,351,000-52.8%
CelLBxHealth Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q12025-03-31-56.5%
Q22025-06-30N/A
Q42025-12-31N/A
CelLBxHealth Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP -0.0931.8%
20232023-12-31GBP -0.08-12.1%
20242024-12-31GBP -0.05-37.6%
20252025-12-31GBP -0.0614.3%
CelLBxHealth Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q12025-03-31-42.6%
Q22025-06-30N/A
Q42025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

£555.00K

-39.3%

Gross Profit

-£4.41M

-854.6%

Gross Margin

-7.94%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

119

N/A

Net Income

-£10.24M

-214.5%

EBITDA

-£5.76M

-80.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

£7.35M

-29.5%

Total Debt

£1.82M

-56.8%

Accounts Receivable

£1.74M

-16.4%

Inventory

£1.30M

-17.9%

Long Term Debt

£1.00M

-70.1%

Short Term Debt

£817.00K

-5.2%

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-£4.76M

-37.4%

Operating Cash Flow

-£4.64M

-39.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GDR.LGenedrive Plc
£0.01+7.69%
FUM.LFutura Medical plc
£0.00-5.01%
RUA.LRUA Life Sciences plc
£0.25-1.96%
PRM.LProteome Sciences plc
£0.02+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About AGL

What is the current price of CelLBxHealth Plc?

CelLBxHealth Plc is trading at N/A per share.

What is the 52-week range for CelLBxHealth Plc?

Over the past 52 weeks, CelLBxHealth Plc has traded between N/A and N/A.

How much debt does CelLBxHealth Plc have?

As of the most recent reporting period, CelLBxHealth Plc reported total debt of £1.82M.

How much cash does CelLBxHealth Plc have on hand?

CelLBxHealth Plc reported £7.35M in cash and cash equivalents in its most recent financial results.

What is CelLBxHealth Plc’s dividend yield?

CelLBxHealth Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services